Sub Supreme Court loves businesses hates people.

Stanford losses – drug company wins and makes even MORE money.

Supreme Court Rules On College and Business Cases
June 6, 2011

The U.S. Supreme Court is now heading down the stretch toward the end of its current term, with major decisions still outstanding, and 27 cases overall yet to be decided. On Monday, the justices issued a variety of opinions of particular interest to the business community, and left intact a California policy that gives illegal aliens in-state college tuition benefits.

Patent ownership
In a patent case with ramifications for universities and corporations, the court ruled in favor of pharmaceutical giant Roche and against Stanford University. At issue in the case was who would reap the financial benefits from the development of a technology that is used in HIV/AIDS test kits sold all around the world by Roche.
The technology was developed by researcher Mark Holodniy at Stanford, using funds from a grant awarded to Stanford by the National Institutes of Health. The university claimed that under an agreement Holodniy signed with the university and under a federal law governing patents developed with federal money, the university was entitled to full ownership of the patent. Roche countered that when Holodniy was on loan to the company for nine months, he signed an agreement that trumped the university’s rights and therefore, that Roche owned the patent on the discovery that Holodniy later developed at Stanford, using some of the information he had access to at Roche.
By a 7-to-2 vote, the Supreme Court sided with Roche, meaning that the pharmaceutical company will reap all the financial benefits of the discovery made on the Stanford campus. Writing for the court majority, Chief Justice John Roberts suggested that universities can avoid such problems in the future by writing tighter contracts for their researchers.
Nonetheless, the decision is a major victory for companies like Roche, Pfizer, Intel, and others that collaborate with universities on research with an eye toward marketing future discoveries.

Leave a Reply

Your email address will not be published. Required fields are marked *